<?xml version="1.0" encoding="UTF-8"?>
<p id="Par5">Although the adverse effects of drugs used to treat rheumatic diseases is a major concern, discussions are also taking place about the potential positive effects of some common rheumatic disease treatments. Antimalarials, JAK inhibitors, IL-1 inhibitors, IL-6 inhibitors, intravenous immunoglobulin and leflunomide have all been put forward as potential treatments for COVID-19. Appropriate trials of these agents are a pre-requisite to their widespread use in treating COVID-19 and are progressing; a phase III trial of tocilizumab for COVID-19 is currently ongoing
 <sup>
  <xref ref-type="bibr" rid="CR10">10</xref>
 </sup>.
</p>
